Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $117.1 million as the latest value for Q3 2021.

  • Quarterly Total Non-Current Liabilities rose 13.23% to $117.1 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $117.1 million through Aug 2021, up 13.23% year-over-year, with the annual reading at $105.2 million for FY2020, 103.02% up from the prior year.
  • Total Non-Current Liabilities for Q3 2021 was $117.1 million at Nurix Therapeutics, down from $119.0 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $125.7 million in Q1 2021, with the low at $51.8 million in Q4 2019.
  • Average Total Non-Current Liabilities over 3 years is $103.7 million, with a median of $111.1 million recorded in 2020.
  • The sharpest move saw Total Non-Current Liabilities surged 103.02% in 2020, then rose 13.23% in 2021.
  • Over 3 years, Total Non-Current Liabilities stood at $51.8 million in 2019, then soared by 103.02% to $105.2 million in 2020, then rose by 11.25% to $117.1 million in 2021.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $117.1 million, $119.0 million, and $125.7 million for Q3 2021, Q2 2021, and Q1 2021 respectively.